Centre Hospitalier Universitaire de Toulouse

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 ClinicalTrials.gov n...

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

Gilteritinib resulted in significantly longer survival and higher percentages of patients with remission than salvage chemotherapy among patients with relapsed or refractory <i>...

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDI...

Liver resection of transplantation for hepatocellular carcinoma?

Kinetics of molecular patterns captured by mannose-binding lectin in septic shock correlate with clinical outcome: a monocentric prospective observational study

Abstract Background Various serum biomarkers and scoring systems are currently employed to manage septic critically ill patients. However, a paucity of biomarker evidence facili...